Download Support of the Head and Neck patient during Radiotherapy

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Support of the Head and
Neck patient during
Radiotherapy/Combined
Chemo-Radiation(CRT)
Anne Hope
Head and Neck CNS
RSCH
AIMS
•
•
•
•
Gain an understanding treatment
implications/toxicities of RT/CRT .
The Role of the Holistic Needs Assessment.
Involvement of MDT
Evidence Based symptom control/supporting
patient.
The Current Practice
• Increase in use of combined Chemo-radiation –
HPV RELATED ?
• Overall increase in 100% over past year.
• Most common sites treated:
Oropharynx/Hypopharynx/Tongue/Larynx.
• Cisplatin /Carboplatin/Cetuximab.
• 5/10/20/30 # RT (Depending on goal/disease)
Pre - Treatment Support
•
•
•
•
•
Introduce to the MDT – attend MPC.
Holistic Assessment
Patient Information/Education
BUDDY ?
Referrals to necessary support services.
Holistic Assessment
Holistic Assessment
• Cancer Reform Strategy (CRS) (2007), Nice
Guidance in supportive and palliative care(2004),
Cancer Action Team (2007).
• Buzz word in Cancer Care
• Peer Review Measure
• Enables MDT approach/Team work
• Encouraged at key points of the Patient journey.
Common ProblemsPsycho-social
•
•
•
•
•
•
•
Withdrawn
Depression
Anxiety
Inability to work
Sexuality/Body Image
Loss of role in family/relationship
Financial difficulty
Common ProblemsClinical
•
•
•
•
•
•
•
•
•
Oral Mucositis
Skin Reaction
Pain
Xerostomia
Dysphagia
Copious/thick secretions
Aspiration
Fatigue
ORN
Oral Mucositis
Presentation
• OM defined as ‘ Inflammation of the mucosal
membrane, often characterised by ulceration
resulting in the impairment of the ability to talk, pain
and dyshagia.’ (Rubenstein et al, 2004)
• 40 % of patients undergoing chemotherapy for solid
tumours.
• 97% receiving RT to H&N will suffer with OM.
Presentation …contd
•
•
•
•
•
•
Pain/Discomfort
Ulceration
Erythema
Dysphagia
Bleeding
Necrotic/sloughy ulceration
Prevention
•
•
•
•
•
•
•
Little evidence/ no avoidance.
Dental Assessment pre treatment.
Necessary dental extractions.
Avoidance alcohol/smoking/spicy foods.
Oral brushing/rinsing after every meal.
Soft tooth brush/Flossing.
High Fluoride Toothpaste.
Management
• Manage symptom e.g pain WHO ladder.
• Use of recognised oral assessment Guide e.g WHO
Oral Toxicity Scale.
• Consistent Assessment…..Daily ?
• Saline mouth rinses QDS/Sodium bicarbonate.
• Asprin Gargles 300mg QDS.
• Topical Agents, e.g Gelclair/Mugard
• Difflam/Corsodyl.
• Preventative Rinses- Caphosol?
• Manage Infections/Candida.
Skin Care
Presentation
• 85% Patient receiving external beam RT will
experience moderate –severe skin reaction.
• 10 % Moist Desquamation.
• Usually seen 10-14 days following first fraction.
• Is not a burn ! – Reaction differs /damage to skin
with RT migrates upwards and effects epidermal
layer only.
• Usually increases up to 7-10 following last treatment.
• 4-6 weeks following completion of treatment skin
healing well.
Radiotherapy starts –
Activates inflammatory
response
Treatment completed- Takes
10-21 days for basal cells to
recover &new skin to grow.
No New cells to replace dead cellsMoist desquamation
Radiotherapy
Cycle
10-14/Days damaged basal
cells migrate to skin surface.
Erythema develops.
Further skin damage.
New Cells reproduce before old dead cells shedDry desquamation .
RTOG Grading Scale
Assessment / Observation Effects of
Radiotherapy on Skin Cells
RTOG 0
No visible change to skin
RTOG 1
Faint or dull erythema. Mild
tightness of skin and itching
may occur
RTOG 2
Bright erythema / dry
desquamation. Sore, itchy and
tight skin
RTOG 2.5
Patchy moist desquamation
Yellow/pale green exudate.
Soreness with oedema
RTOG 3
Confluent moist desquamation.
Yellow/pale green exudate.
Soreness with oedema
RTOG 4
Ulceration, bleeding, necrosis
(rarely seen)
Cetuximab Reaction
Management
•
•
•
•
•
•
•
Priority – To avoid treatment breaks – delays
Maintain comfort/function
Maintain skin integrity.
Reduce pain.
Promote hydrated skin.
To avoid /reduce Infection.
Reduce risk of complications/further trauma.
Management…..contd
• Avoid tight fitting clothing.
• General moisturisers stop-if skin broken.
• Hydrocolloid gel –skin breakdown.
e.g Intrasite Gel.
• Non adhesive dressings- moist desquamation.
• Soft silicone dressings e.g Polymem, Meplilex lite.
Recommendations
• Wash Daily with a simple soap and water.
• Avoid rubbing/irritating affected area.
• Moisturise skin twice daily- Product choice little
evidence.
• However do avoid SLS, Lanolin, products with high
levels of paraffin/petroleum.
• Aquamax- RSCH preference.
• Avoid wet shaving/waxing/hair removal creams.
• Pliazon cream for cetuximab reaction.
• Aveeno cream.
Secretions
•
•
•
•
•
•
•
•
Most Difficult symptom to manage.
Distressing for patient and carers.
Causes Halitosis.
Unsociable !
Thick tenacious phlegm.
Source of infection/aspiration.
Maintains healthy PH oral cavity.
Main cause or nausea/retching.
Mangement
•
•
•
•
•
Good oral hygiene.
Regular rinsing…..saline mouth washes.
?? Sodium Bicarbonate Rinses.
Steam Inhalation.
Nebulisers.
Conclusion
Promote
patient comfort
Control
Symptoms
Complete
proposed
treatment.
Reduce/control
pain
Avoid
admission
Holistic
Assessment
Maintain
nutrition
intake
Avoid
Infection
Avoid
aspiration/maintain
safe swallow
Psychological
support
MDT
Working
Avoid further
trauma to
skin/oral
mucosa